A protein complex called LUBAC enables 'quality control' of the T cells before they are released into the bloodstream.

TOP INSIGHT
Developing new approaches and therapies for switching off autoimmune T cells may help in the prevention of autoimmune condition like Type 1 diabetes and multiple sclerosis.
Only a small proportion of the T cells that begin their development 'graduate' and are allowed out of the thymus, into the bloodstream - the rest do not survive.
Dr Charis Teh, Dr Daniel Gray and colleagues made the discovery, published in the journal Nature Communications, when investigating the link between faulty LUBAC and T cell defects.
Dr Teh said the team were surprised to discover that LUBAC was important for a very late stage of T cell development within the thymus.
"Since the function of the thymus was discovered by Professor Jacques Miller almost 60 years ago, there has been an intense research effort to reveal the intricate details of how immune T cells develop," she said.
In most people, this prevents the development of autoimmune diseases such as type 1 diabetes and multiple sclerosis.
"This may have therapeutic applications in the future for treating autoimmune diseases," Dr Gray said.
The research has provided new insights into how autoimmune disorders are linked to faulty T cell function. This may inspire to new immune-based therapies for these conditions.
Source-Medindia
MEDINDIA




Email





